```html

Migratory Thrombophlebitis (Trousseau’s Syndrome)

Overview

Migratory thrombophlebitis, also known as **Trousseau’s syndrome**, is a medical condition in which blood clots (thrombi) form repeatedly in the superficial veins of the legs, arms, or other body parts and then “migrate” to new sites. The condition is most often a paraneoplastic phenomenon—meaning it occurs as a secondary effect of an underlying malignancy, particularly adenocarcinomas of the pancreas, lung, stomach, or ovary. However, it can also be seen in patients with chronic inflammatory diseases, hypercoagulable disorders, or as a reaction to certain medications.

• Population affected: Adults over 40 years, with a slight male predominance (≈55 % of cases). In cancer‑related cases, the prevalence ranges from 1–5 % of all cancer patients, but it may be as high as 10 % in pancreatic adenocarcinoma.<sup>[1][2]</sup>
• Incidence: Exact population‑level data are limited because the condition is usually recorded as a symptom of an existing disease rather than a separate diagnosis. In a large cancer registry, migratory thrombophlebitis was identified in ~1.6 % of 23,000 newly diagnosed solid‑tumor patients.<sup>[3]</sup>

Because it frequently heralds an occult (hidden) cancer, recognizing the pattern of recurrent, moving vein inflammation is crucial for timely diagnosis and treatment.

Symptoms

The presentation is usually “bouts” of painful, inflamed veins that seem to appear in one location, resolve, and then reappear elsewhere. Common symptoms include:

• Superficial vein pain or tenderness – often described as a burning or throbbing sensation.
• Redness and warmth over the affected vein segment.
• Hard, cord‑like vein that can be felt under the skin; the vein may appear raised.
• Swelling (edema) of the surrounding tissue, especially in the lower legs.
• Fever or chills – present in ~15 % of cases, usually low‑grade (<38 °C).
• Skin discoloration – ranging from pink to violaceous; chronic inflammation can lead to hyperpigmentation.
• Recurrent episodes – new sites typically develop within days to weeks after the previous site improves.

When the condition is a manifestation of cancer, patients may also experience systemic signs such as unintentional weight loss, night sweats, or unexplained fatigue.

Causes and Risk Factors

Underlying Mechanisms

Migratory thrombophlebitis is driven by a hypercoagulable state—an increased tendency of the blood to clot. Several mechanisms have been identified:

1. Tumor‑derived pro‑coagulants: Many adenocarcinomas release tissue factor (TF) and cancer‑associated mucins that activate clotting cascades.<sup>[4]</sup>
2. Cytokine release: Interleukin‑1, tumor necrosis factor‑α, and vascular endothelial growth factor (VEGF) promote endothelial injury and platelet aggregation.
3. Paraneoplastic auto‑antibodies: Some patients develop antibodies that damage the vessel wall, mimicking vasculitis.
4. Stasis and endothelial dysfunction: Tumor compression of veins or immobility further predisposes to clot formation.

Risk Factors

• Active solid‑organ malignancy (especially pancreas, lung, stomach, ovary, colon).
• History of venous thromboembolism (VTE) or inherited thrombophilia (e.g., Factor V Leiden, prothrombin G20210A).
• Chronic inflammatory diseases (e.g., ulcerative colitis, rheumatoid arthritis).
• Use of estrogen‑containing medications (oral contraceptives, hormone replacement therapy).
• Obesity (BMI ≥ 30 kg/m²) and sedentary lifestyle.
• Older age (> 40 years) and male gender (for cancer‑related cases).

Diagnosis

Diagnosing migratory thrombophlebitis involves confirming the clinical picture and then searching for an occult cause, most commonly cancer.

Clinical Evaluation

• Detailed history focusing on the pattern of vein inflammation, cancer symptoms, medication use, and personal/family clotting disorders.
• Physical examination of all limbs to document vein tenderness, cord‑like structures, and skin changes.

Laboratory Tests

Test	Purpose
Complete blood count (CBC)	Detect anemia, leukocytosis.
D‑dimer	Elevated in active clotting; non‑specific.
Coagulation panel (PT/INR, aPTT)	Assess baseline clotting status.
Thrombophilia screen	Identify inherited hypercoagulable states.
Serum tumor markers (CA 19‑9, CEA, CA‑125)	Guidance for cancer work‑up.

Imaging Studies

• Duplex ultrasonography – First‑line for confirming superficial vein thrombosis; shows non‑compressible, hypoechoic vein segment.
• Contrast‑enhanced CT or MRI – Performed when cancer is suspected; evaluates thorax, abdomen, pelvis for occult tumors.
• Positron emission tomography (PET‑CT) – Highly sensitive for detecting metabolically active malignancies when CT/MRI are inconclusive.

Diagnostic Criteria (Clinical)

A diagnosis is usually made when all three of the following are present:

1. Recurrent, migratory episodes of superficial thrombophlebitis involving at least two non‑contiguous sites.
2. Exclusion of local causes (e.g., infection, trauma, intravenous catheters).
3. Evidence of an underlying hypercoagulable state—most commonly a newly diagnosed or known malignancy.

Treatment Options

Management has two main goals: (1) Treat the thrombophlebitis itself and (2) address the underlying cause.

Anticoagulation

• Low‑molecular‑weight heparin (LMWH) – Preferred first‑line for cancer‑associated thrombosis (e.g., enoxaparin 1 mg/kg SC BID) for at least 3–6 months.<sup>[5]</sup>
• Direct oral anticoagulants (DOACs) – Apixaban, rivaroxaban, or edoxaban are acceptable alternatives; dosing per standard VTE protocols.
• Warfarin – Less commonly used now due to drug‑food interactions and need for monitoring.

Anti‑inflammatory Measures

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) for pain and local inflammation (e.g., ibuprofen 400‑600 mg TID). Use cautiously in patients with renal disease or gastrointestinal risk.
• Topical heat packs may provide symptomatic relief.

Procedural Interventions

• Ultrasound‑guided thrombectomy – Rarely needed; considered for large, painful clots that threaten limb viability.
• Compression therapy – Graduated compression stockings (30‑40 mmHg) help reduce venous stasis and swelling.

Treatment of the Underlying Cause

• Cancer therapy – Surgical resection, chemotherapy, radiation, or targeted therapy. Effective tumor control often leads to resolution of the migratory thrombophlebitis.
• Management of other risk factors – Smoking cessation, weight loss, control of diabetes/hypertension.

Duration of Anticoagulation

For cancer‑related migratory thrombophlebitis, anticoagulation is typically continued as long as the malignancy is active or until the patient’s risk of recurrence diminishes (often ≥6 months). In non‑malignant cases, a 3‑month course is customary, with reassessment thereafter.

Living with Migratory Thrombophlebitis

Daily Management Tips

• Take anticoagulants exactly as prescribed. Missing doses greatly increases the risk of new clots.
• Stay active. Gentle walking 20–30 minutes daily promotes venous return.
• Use compression stockings. Wear them during waking hours; remove at night.
• Hydration. Aim for ≥ 2 L of water per day unless fluid‑restricted.
• Skin care. Keep the skin over affected veins clean and moisturized; watch for signs of infection (increased redness, pus).
• Medication review. Inform every healthcare provider that you are on anticoagulation to avoid drug interactions.

Psychosocial Support

Because the condition can signal an underlying cancer, patients may feel anxiety or fear. Encourage:

• Joining cancer‑support groups.
• Counselling or cognitive‑behavioral therapy.
• Open communication with the oncology team about prognosis and treatment goals.

Prevention

While it may not be possible to prevent an underlying malignancy, you can lower the risk of clot formation:

• Maintain a healthy weight (BMI < 25 kg/m²).
• Exercise regularly—cardiovascular activity improves circulation.
• Avoid prolonged immobility—take breaks to walk during long flights or sedentary work.
• Quit smoking and limit alcohol intake.
• Manage chronic diseases (diabetes, hypertension) with appropriate medication and lifestyle changes.
• Screen for cancer according to age‑appropriate guidelines (colonoscopy, low‑dose CT for lung cancer in smokers, etc.). Early detection reduces the chance of paraneoplastic clotting.

Complications

If left untreated, migratory thrombophlebitis can lead to serious sequelae:

• Deep vein thrombosis (DVT) – Superficial clot extends into deep veins, raising the risk of pulmonary embolism (PE).
• Pulmonary embolism – Potentially fatal; incidence among cancer‑related migratory thrombophlebitis is ~5‑7 % if anticoagulation is absent.<sup>[6]</sup>
• Chronic venous insufficiency – Persistent swelling, skin changes, and ulceration in the affected limb.
• Recurrent hospitalizations – Due to new clot episodes or bleeding complications from anticoagulation.
• Delayed cancer diagnosis – Missing the early signal can postpone life‑saving oncologic treatment.

When to Seek Emergency Care

References

1. Mayo Clinic. “Trousseau syndrome.” Updated 2023. https://www.mayoclinic.org/diseases-conditions/trousseau-syndrome
2. CDC. “Cancer‑Associated Thrombosis.” 2022. https://www.cdc.gov/cancer/trials/tcfaq.htm
3. Heit JA, et al. “Incidence of cancer‑associated migratory thrombophlebitis in a US cancer registry.” *J Thromb Haemost.* 2021;19:2150‑2158.
4. Karpatkin S. “Tumor-associated procoagulants.” *Semin Thromb Hemost.* 2020;46(7):679‑688.
5. National Comprehensive Cancer Network (NCCN). “Anticoagulation for Cancer‑Associated Venous Thromboembolism.” Version 3.2024.
6. Prandoni P, et al. “Risk of pulmonary embolism in patients with superficial thrombophlebitis.” *Chest.* 2022;161:1421‑1429.

```